Cardiometabolic & kidneyCohort study
Effect of sodium-glucose cotransporter-2 inhibitors on kidney outcomes of individuals with type 2 diabetes according to blood pressure levels
- Retrospective cohort study
- propensity-score matched (1:2)
- nationwide
Authors' conclusion
This nationwide cohort analysis demonstrated that the kidney-protective effect of SGLT2 inhibitors could be modified by baseline SBP
Study context
- Population
- Individuals newly prescribed SGLT2 or DPP4 inhibitors for T2DM, nationwide epidemiological cohortmatched cohort
- Participants
- 2,148 vs 4,296
- Exposure
- SGLT2 inhibitors vs DPP4 inhibitors
- SGLT2 inhibitorn = 2,148
- DPP4 inhibitorn = 4,296reference
- Outcome
- Annual eGFR decline
Main finding
As reported in the abstract
SGLT2 inhibitor
−1.32
mL/min/1.73 m²
DPP4 inhibitor
−1.50
mL/min/1.73 m²
- Treatment effect of SGLT2 inhibitors over DPP4 inhibitors augmented with higher systolic BP (SBP)
- P for interaction = 0.0199
Observational data: associations, not effects.
Further findings
30% or 40% reduction in estimated glomerular filtration rate (eGFR)
- Advantages of SGLT2 inhibitors persisted, with a trend of augmented effect with higher SBP
Annual eGFR decline, females with lower SBP (subgroup)
- eGFR decline exacerbated with SGLT2 inhibitors vs DPP4 inhibitors
Original publication
Effect of sodium-glucose cotransporter-2 inhibitors on kidney outcomes of individuals with type 2 diabetes according to blood pressure levels. Eur J Prev Cardiol. Published 18 March 2025. doi:10.1093/eurjpc/zwaf156
Summarised from the published abstract; every number is checked against it